Twist Bioscience Corp's stock surged 5.02% during Tuesday's intraday trading session, following a positive analyst note from Barclays.
The price movement comes after Barclays analyst Luke Sergott maintained a Buy rating on the stock with a price target of $65.00 in a report released pre-market. Such analyst endorsements often influence investor sentiment and trading activity.